Patents by Inventor James N. Campbell
James N. Campbell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180311189Abstract: The invention provides methods for treating acral lick granuloma in a canine using a capsaicinoid, such as capsaicin. The invention also provides methods for deactivating a nerve fiber selected from the group consisting of a C-fiber and an A-delta fiber, each being located in or proximal to an acral lick granuloma in a canine, using a capsaicinoid, such as capsaicin.Type: ApplicationFiled: November 13, 2015Publication date: November 1, 2018Inventors: James N. Campbell, Peter D. Hanson
-
Publication number: 20180296506Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: December 8, 2017Publication date: October 18, 2018Inventors: James N. Campbell, Arthur F. Michaelis
-
Publication number: 20170014359Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: June 16, 2016Publication date: January 19, 2017Inventors: James N. Campbell, Arthur F. Michaelis
-
Patent number: 9370500Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: GrantFiled: February 21, 2012Date of Patent: June 21, 2016Assignee: Centrexion Therapeutics CorporationInventors: James N. Campbell, Arthur F. Michaelis
-
Publication number: 20150093435Abstract: Compositions, and methods of use thereof, are provided for the treatment of painful neuropathy by local or topical delivery of compounds that interact with ?-adrenergic receptors, especially an alpha2 adrenergic agonist such as clonidine, to the entire painful area such that the need for systemic dosing is minimized. The compounds are delivered to or adjacent to painful areas in patients with painful length dependent neuropathy, and other neuropathies that affect the pain signaling fibers in the skin. A preferred compound for the treatment of patients with length dependent neuropathy is clonidine applied in a transdermal patch, gel, ointment, lotion, liposomal formulation, cream, or emulsion, wherein the concentration is sufficient to provide an effective dose in the painful area or immediately adjacent areas.Type: ApplicationFiled: December 9, 2014Publication date: April 2, 2015Inventor: James N. Campbell
-
Patent number: 8962668Abstract: Compositions, and methods of use thereof, are provided for the treatment of painful neuropathy by local or topical delivery of compounds that interact with ?-adrenergic receptors, especially an alpha2 adrenergic agonist such as clonidine, to the entire painful area such that the need for systemic dosing is minimized. The compounds are delivered to or adjacent to painful areas in patients with painful length dependent neuropathy, and other neuropathies that affect the pain signaling fibers in the skin. A preferred compound for the treatment of patients with length dependent neuropathy is clonidine applied in a transdermal patch, gel, ointment, lotion, liposomal formulation, cream, or emulsion, wherein the concentration is sufficient to provide an effective dose in the painful area or immediately adjacent areas.Type: GrantFiled: February 21, 2011Date of Patent: February 24, 2015Assignee: Arcion Therapeutics, Inc.Inventor: James N. Campbell
-
Publication number: 20150018387Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit neuropathic pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: September 11, 2014Publication date: January 15, 2015Inventors: James N. Campbell, Arthur F. Michaelis
-
Publication number: 20120149779Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Inventors: James N. Campbell, Arthur F. Michaelis
-
Patent number: 8119694Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: GrantFiled: August 17, 2009Date of Patent: February 21, 2012Assignee: Arcion Therapeutics, Inc.Inventors: James N. Campbell, Arthur F. Michaelis
-
Publication number: 20120015939Abstract: Alpha-2 adrenergic agonists such as clonidine may be used to treat the pain associated with painful diabetic neuropathy (PDN) only in a subset of these patients. Targeted nociceptors (pain fibers) must be functionally expressed in the skin in order for clonidine to have a therapeutic effect. Neuropathies associated with pain differ with respect to the expression of nociceptors in the skin. Clonidine targets alpha-2 adrenergic receptors on the terminals of nociceptors. The presence of the targeted nociceptors may be determined by topical application of a TRPV1 agonist such as capsaicin. Patients who detect the capsaicin as a pain stimulus applied near the painful area have expression in the skin of the requisite targeted nociceptors and the targeted alpha-2 adrenergic receptors. The test is referred to as a capsaicin challenge test. This test significantly improves clinical outcomes in topical neuropathic pain treatment.Type: ApplicationFiled: July 18, 2011Publication date: January 19, 2012Inventor: James N. Campbell
-
Patent number: 8026266Abstract: Compositions, and methods of use thereof, are provided for the treatment of painful neuropathy by local or topical delivery of compounds that interact with ?-adrenergic receptors, especially an alpha2 adrenergic agonist such as clonidine, to the entire painful area such that the need for systemic dosing is minimized. The compounds are delivered to or adjacent to painful areas in patients with painful length dependent neuropathy, and other neuropathies that affect the pain signaling fibers in the skin. A preferred compound for the treatment of patients with length dependent neuropathy is clonidine applied in a transdermal patch, gel, ointment, lotion, liposomal formulation, cream, or emulsion, wherein the concentration is sufficient to provide an effective dose in the painful area or immediately adjacent areas.Type: GrantFiled: November 7, 2006Date of Patent: September 27, 2011Assignee: Arcion Therapeutics, Inc.Inventor: James N. Campbell
-
Publication number: 20110142920Abstract: Compositions, and methods of use thereof, are provided for the treatment of painful neuropathy by local or topical delivery of compounds that interact with ?-adrenergic receptors, especially an alpha2 adrenergic agonist such as clonidine, to the entire painful area such that the need for systemic dosing is minimized. The compounds are delivered to or adjacent to painful areas in patients with painful length dependent neuropathy, and other neuropathies that affect the pain signaling fibers in the skin. A preferred compound for the treatment of patients with length dependent neuropathy is clonidine applied in a transdermal patch, gel, ointment, lotion, liposomal formulation, cream, or emulsion, wherein the concentration is sufficient to provide an effective dose in the painful area or immediately adjacent areas.Type: ApplicationFiled: February 21, 2011Publication date: June 16, 2011Inventor: James N. Campbell
-
Publication number: 20100041765Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: August 17, 2009Publication date: February 18, 2010Inventors: James N. Campbell, Arthur F. Michaelis
-
Publication number: 20090048296Abstract: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit neuropathic pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful area or immediately adjacent areas, to ameliorate or eliminate the pain. High concentration of local anesthetic in solution in the carrier is used to drive rapid release and uptake of the drug. Relief is typically obtained for a period of several hours.Type: ApplicationFiled: August 15, 2008Publication date: February 19, 2009Inventors: James N. Campbell, Arthur F. Michaelis
-
Patent number: 7333857Abstract: The method disclosed herein entails spinal cord stimulation via electrodes placed directly into the dorsal horn, dorsal column, spinothalamic tract, nucleus cuneatus, nucleus gracilis, spinal tract of V, or spinal nucleus of V (nucleus caudalis) depending on the source of pain. This “intramedullary” stimulation “jams” or otherwise prevents the pain signal from being transmitted. The method provides a means to stimulate the targeted area directly, creating a stable means of stimulating the desired area, and decreasing stimulation of other structures.Type: GrantFiled: July 16, 2004Date of Patent: February 19, 2008Assignee: Arcl, Inc.Inventor: James N. Campbell
-
Patent number: 6559186Abstract: Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an &agr;-1-adrenergic antagonist, &agr;-2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.Type: GrantFiled: August 5, 1994Date of Patent: May 6, 2003Assignee: Arc 1, Inc.Inventor: James N. Campbell
-
Patent number: 5962532Abstract: Methods and compositions for treating pain at a specific site with an effective concentration of capsaicin or analogues thereof are described. The methods involve providing anesthesia to the site where the capsaicin or analogues thereof is to be administered, and then administering an effective concentration of capsaicin to the joint. The anesthesia can be provided directly to the site, or at remote site that causes anesthesia at the site where the capsaicin is to be administered. For example, epidural regional anesthesia can be provided to patients to which the capsaicin is to be administered at a site located from the waist down. By pretreating the site with the anesthetic, a significantly higher concentration of capsaicin can be used. Effective concentrations of capsaicin or analogues thereof range from between 0.01 and 10% by weight, preferably between 1 and 7.5% by weight, and more preferably, about 5% by weight.Type: GrantFiled: March 12, 1998Date of Patent: October 5, 1999Inventors: James N. Campbell, Marco Pappagallo, Richard A. Meyer
-
Patent number: 5447947Abstract: Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an .alpha.-adrenergic antagonist, .alpha.-1-adrenergic antagonist, .alpha.2 adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine. Examples demonstrate relief of pain by application of phentolamine or clonidine.Type: GrantFiled: June 25, 1992Date of Patent: September 5, 1995Assignee: ARC 1Inventor: James N. Campbell
-
Patent number: 5070084Abstract: Method of diagnosing and treatment of sympathetically maintained pain. Sympathetically maintained pain is diagnosed and treated using the method of injecting or transdermally applying an .alpha.-adrenergic blocking agent selected from the group consisting of .alpha.-adrenergic antagonist, .alpha.-1-adrenergic antagonist, .alpha.2 adrenergic agonist, or other drug that depletes sympathetic norepineprhine. Sympathetic efferent fibers release norepinephrine which in turn activates .alpha.-adrenergic receptors. Activation of these receptors, either directly or indirectly, excites nociceptors. Activity in the nociceptors then evokes pain, and causes further discharge of nociceptors. Intravenous administration of phentolamine blocks the activation of .alpha.-adrenergic receptors which causes the pain to be relieved. The use of a clonidine, another .alpha.-adrenergic blocking agent, in a patch similarly achieved substantive pain reduction.Type: GrantFiled: February 26, 1990Date of Patent: December 3, 1991Inventor: James N. Campbell
-
Patent number: RE41998Abstract: Sympathetically maintained pain is treated topically by administering to the site where sympathetically maintained pain is present an ?-1-adrenergic antagonist, ?-2-adrenergic agonist, or other drug that depletes or blocks synthesis of sympathetic norepinephrine, known collectively as sympatholytic agents. Chemical formulas for several sympatholytic agents are given.Type: GrantFiled: May 5, 2005Date of Patent: December 14, 2010Assignee: Arclon Therapeutics, Inc.Inventor: James N. Campbell